Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid plus chemotherapy or with all-transretinoic acid plus arsenic trioxide
- 3 November 2014
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 56 (5), 1342-1345
- https://doi.org/10.3109/10428194.2014.953143
Abstract
The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.Keywords
This publication has 27 references indexed in Scilit:
- From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaBlood, 2011
- Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemiaProceedings of the National Academy of Sciences, 2009
- Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2009
- Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab OzogamicinJournal of Clinical Oncology, 2009
- Precursor T-Lymphoblastic Lymphoma as a Secondary Malignancy in a Young Patient after Successful Treatment of Acute Promyelocytic LeukemiaOnkologie, 2009
- Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2)American Journal of Hematology, 2005
- Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experienceLeukemia, 2003
- Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two casesCancer Genetics and Cytogenetics, 2003
- Therapy-related Acute Myeloid Leukemia and Myelodysplasia after Successful Treatment of Acute Promyelocytic LeukemiaLeukemia & Lymphoma, 2002
- Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemiaBritish Journal of Haematology, 2001